No Record Found
Sector
PharmaceuticalsOpen
₹407Prev. Close
₹409.15Turnover(Lac.)
₹13.01Day's High
₹407Day's Low
₹403.9552 Week's High
₹50052 Week's Low
₹293.53Book Value
₹176.65Face Value
₹10Mkt Cap (₹ Cr.)
706.14P/E
22.19EPS
18.25Divi. Yield
0No Record Found
Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 16.08 | 20.58 | 18.08 | 15.49 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 206.84 | 175.35 | 159.95 | 147.44 |
Net Worth | 222.92 | 195.93 | 178.03 | 162.93 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
---|---|---|---|---|
Revenue | 70.01 | 60.76 | 96.41 | 50.45 |
yoy growth (%) | 15.21 | -36.97 | 91.08 | 79.31 |
Raw materials | -39.06 | -35.75 | -52.98 | -25.9 |
As % of sales | 55.79 | 58.83 | 54.95 | 51.34 |
Employee costs | -5.21 | -5.65 | -5.22 | -4.21 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 7.5 | 5.22 | 19.52 | 7.15 |
Depreciation | -1.14 | -1.15 | -1.2 | -1.19 |
Tax paid | -1.35 | -0.76 | -4.75 | -0.96 |
Working capital | -1.1 | -5.99 | 6.43 | 6.49 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 15.21 | -36.97 | 91.08 | 79.31 |
Op profit growth | 276.91 | -91.66 | 197.85 | -2,095.55 |
EBIT growth | 39.14 | -70.16 | 178.12 | -1,655.73 |
Net profit growth | 38.1 | -69.81 | 138.33 | -17,121.7 |
Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|---|
Gross Sales | 198.32 | 154.37 | 139.6 | 114.23 | 68.52 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 198.32 | 154.37 | 139.6 | 114.23 | 68.52 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 11.16 | 4.48 | 2.92 | 2.91 | 2.67 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,640.2 | 78.98 | 3,93,418.96 | 753.53 | 0.98 | 5,566.68 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,028 | 68.48 | 1,59,985.97 | 557 | 0.5 | 2,357 | 561.08 |
Cipla Ltd CIPLA | 1,592.8 | 24.9 | 1,28,659.07 | 1,303.13 | 1 | 4,501.66 | 397.38 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,647.4 | 62.1 | 1,23,442.43 | 551 | 0.16 | 2,567 | 224.34 |
Mankind Pharma Ltd MANKIND | 2,600.1 | 59.31 | 1,07,334.24 | 412.76 | 0 | 2,541.36 | 354.71 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Mukund P Mehta
Whole-time Director
Bhavin M Mehta
Independent Director
Hemang Engineer
Managing Director
Mira Bhavin Mehta
Independent Director
Murti Vasudev Krishna
Independent Director
Venkita Subramanian Rajan
Company Sec. & Compli. Officer
Pushpa Nyoupane
Independent Director
Dipen Jayantilal Jain
C-301/2 MIDC TTC Indl Area,
Pawane Village,
Maharashtra - 400705
Tel: 91-022-27670322/27680913/65144185
Website: http://www.kilitch.com
Email: info@kilitch.com
C-101 247 Park,
L B S Marg, Vikhroli West,
Mumbai-400083
Tel: 91-22-49186000
Website: www.linkintime.co.in
Email: paytm.ipo@linkintime.co.in
Summary
Kilitch Drugs (India) Limited (KDIL), incorporated in May, 1992 is the one of the leading and fastest growing pharmaceutical companies in the world, manufacturing, supplying and marketing broad range ...
Read More
Reports by Kilitch Drugs (India) Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.